Assessment of serum flecainide trough levels in patients with tachyarrhythmia

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 1, 2005, Pages 47-51

  Homma, Masato ^a   Kuga, Keisuke ^a   Doki, Kosuke ^a   Katori, Kumi ^a   Yamaguchi, Iwao ^a   Sugibayashi, Kenji ^b   Kohda, Yukinao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARTEOLOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FAMOTIDINE; FLECAINIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; NADOLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; QUINAPRIL; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG RESPONSE; EVALUATION; FEMALE; HEART PALPITATION; HUMAN; MALE; OUTPATIENT; QRS COMPLEX; TACHYCARDIA;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; HUMANS; MALE; MIDDLE AGED; SPECTROPHOTOMETRY, ULTRAVIOLET; TACHYCARDIA;

EID: 11144277314     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357055128     Document Type: Article

References (22)

1. Caplin, J. L., Johnston, A., Hamer, J., Camm, A. J. (1985) The acute changes in serum binding of disopyramide and flecainide after myocardial infarction. Eur. J. Clin. Pharmacol. 28: 253-255
2. Conard, G. J., Cronheim, G. E., Klempt, H. W. (1982) Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients. Arzneimittelforschung 32: 55-59
3. Crozier, I. G., Ikram, H., Kenealy, M., Levy, L. (1987) Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. Am. J. Cardiol. 59: 607-609
4. Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L. (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324: 781-788
5. Forland, S. C., Burgess, E., Blair, A. D., Cutler, R. E., Kvam, D. C., Weeks, C. E., Fox, J. M., Conard, G. J. (1988a) Oral flecainide pharmacokinetics in patients with impaired renal function. J. Clin. Pharmacol. 28: 259-267
6. Forland, S. C., Cutler, R. E., McQuinn, R. L., Kvam, D. C., Miller, A. M., Conard, G. J., Parish, S. (1988b) Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J. Clin. Pharmacol. 28: 727-735
7. Griese, E. U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuven, T., Eichelbaum, M. (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26
8. Gross, A. S., Mikus, G., Fischer, C., Hertrampf, R., Gundert-Remy, U., Eichelbaum, M. (1989) Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br. J. Clin. Pharmacol. 28: 555-566
9. Katori, K., Homma, M., Kuga, K., Yamaguchi, I., Sugibayashi, K., Kohda, Y. (2003) Liquid Chromatographic determination of unbound flecainide in therapeutic drug monitoring. J. Pharm. Biomed. Anal. 32: 375-380
10. Kreeger, R. W., Hammill, S. C. (1987) New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin. Proc. 62: 1033-1050
11. McQuinn, R. L., Quarfoth, G. J., Johnson, J. D., Banitt, E. H., Pathre, S. V., Chang, S. F., Ober, R. E., Conard, G. J. (1984) Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab. Dispos. 12: 414-420
12. McQuinn, R. L., Pentikainen, P. J., Chang, S. F., Conard, G. J. (1988) Pharmacokinetics of flecainide in patients with cirrhosis of the liver. Clin. Pharmacol. Ther. 44: 566-572
13. Mikus, G., Gross, A. S., Beckmann, J., Hertrampf, R., Gundert-Remy, U., Eichelbaum, M. (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin. Pharmacol. Ther. 45: 562-567
14. Morganroth, J., Horowitz, L. N. (1984) Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am. J. Cardiol. 53: 89B-94B
15. Munafo, A., Buclin, T., Tuto, D., Biollaz, J. (1992) The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Eur. J. Clin. Pharmacol. 43: 441-443
16. Nakagawa, R., Homma, M., Kuga, K., Yamaguchi, I., Kobayashi, D., Morimoto, Y., Kohda, Y. (2002) High performance liquid chromatography for routine monitoring of serum flecainide. J. Pharm. Biomed. Anal. 30: 171-174
17. Nishida, Y., Fukuda, T., Yamamoto, I., Azuma, J. (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10: 567-570
18. Padrini, R., Piovan, D., Busa, M., al-Bunni, M., Maiolino, P., Ferrari, M. (1993) Pharmacodynamic variability of flecainide assessed by QRS changes. Clin. Pharmacol. Ther. 53: 59-64
19. Roden, D. M., Woosley, R. L. (1986) Drug therapy. Flecainide. N. Engl. J. Med. 315: 36-41
20. Tjandra-Maga, T. B., van Hecken, A., van Melle, P., Verbesselt, R., de Schepper, P. J. (1986) Altered pharmacokinetics of oral flecainide by cimetidine. Br. J. Clin. Pharmacol. 22: 108-110
21. Williams, A. J., McQuinn, R. L., Walls, J. (1988) Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin. Pharmacol. Ther. 43: 449-455
22. Zordan, R., Padrini, R., Bernini, V., Piovan, D., Ferrari, M. (1993) Influence of age and gender on the in vitro serum protein binding of flecainide. Pharmacol. Res. 28: 259-264